PDL BioPharma Inc  

(Public, NASDAQ:PDLI)   Watch this stock  
Find more results for pdli
7.17
+0.15 (2.14%)
Real-time:   10:55AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.99 - 7.18
52 week 6.52 - 10.26
Open 7.07
Vol / Avg. 1.28M/3.12M
Mkt cap 1.17B
P/E 3.93
Div/yield 0.15/8.37
EPS 1.82
Shares 162.75M
Beta 0.62
Inst. own 99%
May 28, 2015
PDL BioPharma Inc Annual Shareholders Meeting - 1:00PM EDT - Add to calendar
May 11, 2015
Q1 2015 PDL BioPharma Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 4, 2015
PDL BioPharma Inc at Cowen Health Care Conference
Feb 25, 2015
PDL BioPharma Inc at RBC Healthcare Conference
Feb 23, 2015
Q4 2014 PDL BioPharma Inc Earnings Call - Webcast
Feb 23, 2015
Q4 2014 PDL BioPharma Inc Earnings Release
Feb 9, 2015
PDL BioPharma Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 47.04% 55.44%
Operating margin 84.86% 92.94%
EBITD margin - 93.99%
Return on average assets 22.75% 42.79%
Return on average equity 51.22% 112.29%
Employees 10 -
CDP Score - -

Address

932 Southwood Blvd
INCLINE VILLAGE, NV 89451
United States - Map
+1-775-8328500 (Phone)
+1-775-8328501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014. It has entered into licensing agreements with numerous entities that are independently developing or have developed humanized antibodies under which it has licensed certain rights under its Queen et al. patents to make, use, sell, offer for sale and import humanized antibodies.

Officers and directors

John P. McLaughlin President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Peter S. Garcia Chief Financial Officer, Vice President
Age: 52
Bio & Compensation  - Reuters
David Montez CPA Chief Accounting Officer, Controller
Age: 40
Bio & Compensation  - Reuters
Christopher Lewis Stone J.D. Vice President, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
Danny Hart Vice President - Business Development
Age: 38
Bio & Compensation  - Reuters
Nathan Kryszak Senior Counsel
Bio & Compensation  - Reuters
David W. Gryska Independent Director
Age: 58
Bio & Compensation  - Reuters
Jody S. Lindell Independent Director
Age: 62
Bio & Compensation  - Reuters
Paul W. Sandman Independent Director
Age: 66
Bio & Compensation  - Reuters
Harold E. Selick Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters